Rodriguez-Vieitez, Elena http://orcid.org/0000-0002-6639-8141
Montal, Victor http://orcid.org/0000-0002-5714-9282
Sepulcre, Jorge http://orcid.org/0000-0002-4199-2304
Lois, Cristina
Hanseeuw, Bernard
Vilaplana, Eduard
Schultz, Aaron P.
Properzi, Michael J.
Scott, Matthew R.
Amariglio, Rebecca
Papp, Kathryn V.
Marshall, Gad A.
Fortea, Juan
Johnson, Keith A.
Sperling, Reisa A.
Vannini, Patrizia http://orcid.org/0000-0002-9425-1059
Funding for this research was provided by:
US National Institute of Aging - NIH grants
Alzheimerfonden, Demensfonden, Erik and Edith Fernström Foundation, Karolinska Institutet Foundation
US National Institute of Aging - NIH
Article History
Received: 12 May 2021
Revised: 16 August 2021
Accepted: 3 September 2021
First Online: 29 September 2021
Competing interests
: The authors declare no competing interests with regards to the content or interpretation of the data in the present study. BH reported grants from the Belgian National Fund for Scientific Research and the Belgian Foundation for Alzheimer Research during the conduct of the study, and personal fees paid to his institution from Roche, Biogen and GE Healthcare outside the submitted work. APS has served on medical advisory boards for Janssen Pharmaceuticals and Biogen. KVP has served as an advisor to Biogen Idec and Digital Cognition Technologies. GAM has received research salary support from Eisai Inc., Eli Lilly, Janssen Alzheimer Immunotherapy, Novartis, and Genentech, and consulting fees from Grifols Shared Services North America, Inc., Eisai Inc., and Pfizer. JF has served as a consultant for Novartis and Lundbeck, has received honoraria for lectures from Roche, NovoNordisk, Esteve and Biogen, and has served at advisory boards for AC Immune, Zambon and Lundbeck. KAJ and RAS are involved in public–private partnership clinical trials sponsored by the NIH and Eli Lilly and Co., who owns the distribution rights to Flortaucipir (AV-1451), but they do not have any personal financial relationship with Eli Lilly. All other authors report no competing interests.